IL2RA (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "IL2RA" in English language version.

refsWebsite

Global rank English rank

37nih.gov

4^th place

24doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

3ensembl.org

1,626^th place

1,007^th place

2harvard.edu

18^th place

17^th place

1genecards.org

low place

1uniprot.org

5,673^rd place

6,418^th place

1web.archive.org

1^st place

1europa.eu

68^th place

117^th place

1uzh.ch

3,633^rd place

3,091^st place

doi.org

Spolski R, Li P, Leonard WJ (October 2018). "Biology and regulation of IL-2: from molecular mechanisms to human therapy". Nature Reviews. Immunology. 18 (10): 648–659. doi:10.1038/s41577-018-0046-y. PMID 30089912. S2CID 51939991.
Zhou P (October 2022). "Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity". Cytokine & Growth Factor Reviews. 67: 80–88. doi:10.1016/j.cytogfr.2022.06.003. PMID 35803833. S2CID 250200065.
Leonard WJ, Donlon TA, Lebo RV, Greene WC (June 1985). "Localization of the gene encoding the human interleukin-2 receptor on chromosome 10". Science. 228 (4707): 1547–1549. Bibcode:1985Sci...228.1547L. doi:10.1126/science.3925551. PMID 3925551.
Buhelt S, Søndergaard HB, Oturai A, Ullum H, von Essen MR, Sellebjerg F (June 2019). "Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls". Cells. 8 (6): 634. doi:10.3390/cells8060634. PMC 6628508. PMID 31242590.
Pourakbari R, Hosseini M, Aslani S, Ayoubi-joshaghani MH, Valizadeh H, Roshangar L, et al. (September 2020). "Association between interleukin 2 receptor A gene polymorphisms (rs2104286 and rs12722489) with susceptibility to multiple sclerosis in Iranian population". Meta Gene. 25: 100750. doi:10.1016/j.mgene.2020.100750.
Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C (April 2007). "Toward further mapping of the association between the IL2RA locus and type 1 diabetes". Diabetes. 56 (4): 1174–1176. doi:10.2337/db06-1555. PMID 17395754.
Qu HQ, Bradfield JP, Bélisle A, Grant SF, Hakonarson H, Polychronakos C (December 2009). "The type I diabetes association of the IL2RA locus". Genes and Immunity. 10 (Suppl 1): S42 – S48. doi:10.1038/gene.2009.90. PMC 2805446. PMID 19956099.
Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, et al. (September 2007). "Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes". Nature Genetics. 39 (9): 1074–1082. doi:10.1038/ng2102. PMID 17676041. S2CID 13940200.
Abel AM, Yang C, Thakar MS, Malarkannan S (2018-08-13). "Natural Killer Cells: Development, Maturation, and Clinical Utilization". Frontiers in Immunology. 9: 1869. doi:10.3389/fimmu.2018.01869. PMC 6099181. PMID 30150991.
Li Y, Li X, Geng X, Zhao H (October 2022). "The IL-2A receptor pathway and its role in lymphocyte differentiation and function". Cytokine & Growth Factor Reviews. 67: 66–79. doi:10.1016/j.cytogfr.2022.06.004. PMID 35803834. S2CID 250252097.
Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD (July 2012). "Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG". European Journal of Immunology. 42 (7): 1893–1905. doi:10.1002/eji.201242444. PMID 22585674.
El-Maraghy N, Ghaly MS, Dessouki O, Nasef SI, Metwally L (August 2018). "CD4+CD25-Foxp3+ T cells as a marker of disease activity and organ damage in systemic lupus erythematosus patients". Archives of Medical Science. 14 (5): 1033–1040. doi:10.5114/aoms.2016.63597. PMC 6111364. PMID 30154885.
Shipkova M, Wieland E (September 2012). "Surface markers of lymphocyte activation and markers of cell proliferation". Clinica Chimica Acta; International Journal of Clinical Chemistry. 413 (17–18): 1338–1349. doi:10.1016/j.cca.2011.11.006. PMID 22120733.
Flynn MJ, Hartley JA (October 2017). "The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer". British Journal of Haematology. 179 (1): 20–35. doi:10.1111/bjh.14770. PMID 28556984.
Jones D, Ibrahim S, Patel K, Luthra R, Duvic M, Medeiros LJ (August 2004). "Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy". Clinical Cancer Research. 10 (16): 5587–5594. doi:10.1158/1078-0432.CCR-0721-03. PMID 15328201.
Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. (March 2013). "Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity". Clinical Immunology. 146 (3): 248–261. doi:10.1016/j.clim.2013.01.004. PMC 3594590. PMID 23416241.
Peerlings D, Mimpen M, Damoiseaux J (2021). "The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis". Journal of Translational Autoimmunity. 4: 100123. doi:10.1016/j.jtauto.2021.100123. PMC 8716671. PMID 35005590.
Kalia V, Sarkar S (2018-12-20). "Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act". Frontiers in Immunology. 9: 2987. doi:10.3389/fimmu.2018.02987. PMC 6306427. PMID 30619342.
Damoiseaux J (September 2020). "The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor". Clinical Immunology. 218: 108515. doi:10.1016/j.clim.2020.108515. PMID 32619646.
Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, et al. (November 2004). "Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma". Blood. 104 (10): 3355–3357. doi:10.1182/blood-2003-11-3922. PMID 15205267.
Kaya H, Kaji M, Usuda D (April 2021). "Soluble interleukin-2 receptor levels on admission associated with mortality in coronavirus disease 2019". International Journal of Infectious Diseases. 105: 522–524. doi:10.1016/j.ijid.2021.03.011. PMC 7942057. PMID 33711520.
Mengel J, Cardillo F, Pontes-de-Carvalho L (2016-05-13). "Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for Which There Is No Treatment". Frontiers in Microbiology. 7: 675. doi:10.3389/fmicb.2016.00675. PMC 4866556. PMID 27242702.
Sahin D, Arenas-Ramirez N, Rath M, Karakus U, Hümbelin M, van Gogh M, et al. (December 2020). "An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer". Nature Communications. 11 (1): 6440. Bibcode:2020NatCo..11.6440S. doi:10.1038/s41467-020-20220-1. PMC 7755894. PMID 33353953.
Pfender N, Martin R (December 2014). "Daclizumab (anti-CD25) in multiple sclerosis" (PDF). Experimental Neurology. 262 (Pt A): 44–51. doi:10.1016/j.expneurol.2014.04.015. PMID 24768797. S2CID 32444028.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000134460 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000026770 – Ensembl, May 2017

ensembl.org

"Gene: IL2RA (ENSG00000134460) - Orthologues - Homo_sapiens - Ensembl genome browser 108". www.ensembl.org. Retrieved 2023-01-25.

europa.eu

ema.europa.eu

"Zinbryta Summary of Product Characteristics" (PDF). European Medicines Agency. 2016. Archived from the original (PDF) on 2018-06-14. Retrieved 2016-12-09.

genecards.org

"IL2RA Gene - GeneCards | IL2RA Protein | IL2RA Antibody". www.genecards.org. Retrieved 2023-01-25.

harvard.edu

ui.adsabs.harvard.edu

Leonard WJ, Donlon TA, Lebo RV, Greene WC (June 1985). "Localization of the gene encoding the human interleukin-2 receptor on chromosome 10". Science. 228 (4707): 1547–1549. Bibcode:1985Sci...228.1547L. doi:10.1126/science.3925551. PMID 3925551.
Sahin D, Arenas-Ramirez N, Rath M, Karakus U, Hümbelin M, van Gogh M, et al. (December 2020). "An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer". Nature Communications. 11 (1): 6440. Bibcode:2020NatCo..11.6440S. doi:10.1038/s41467-020-20220-1. PMC 7755894. PMID 33353953.

nih.gov

pubmed.ncbi.nlm.nih.gov

Spolski R, Li P, Leonard WJ (October 2018). "Biology and regulation of IL-2: from molecular mechanisms to human therapy". Nature Reviews. Immunology. 18 (10): 648–659. doi:10.1038/s41577-018-0046-y. PMID 30089912. S2CID 51939991.
Zhou P (October 2022). "Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity". Cytokine & Growth Factor Reviews. 67: 80–88. doi:10.1016/j.cytogfr.2022.06.003. PMID 35803833. S2CID 250200065.
Leonard WJ, Donlon TA, Lebo RV, Greene WC (June 1985). "Localization of the gene encoding the human interleukin-2 receptor on chromosome 10". Science. 228 (4707): 1547–1549. Bibcode:1985Sci...228.1547L. doi:10.1126/science.3925551. PMID 3925551.
Buhelt S, Søndergaard HB, Oturai A, Ullum H, von Essen MR, Sellebjerg F (June 2019). "Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls". Cells. 8 (6): 634. doi:10.3390/cells8060634. PMC 6628508. PMID 31242590.
Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C (April 2007). "Toward further mapping of the association between the IL2RA locus and type 1 diabetes". Diabetes. 56 (4): 1174–1176. doi:10.2337/db06-1555. PMID 17395754.
Qu HQ, Bradfield JP, Bélisle A, Grant SF, Hakonarson H, Polychronakos C (December 2009). "The type I diabetes association of the IL2RA locus". Genes and Immunity. 10 (Suppl 1): S42 – S48. doi:10.1038/gene.2009.90. PMC 2805446. PMID 19956099.
Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, et al. (September 2007). "Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes". Nature Genetics. 39 (9): 1074–1082. doi:10.1038/ng2102. PMID 17676041. S2CID 13940200.
Abel AM, Yang C, Thakar MS, Malarkannan S (2018-08-13). "Natural Killer Cells: Development, Maturation, and Clinical Utilization". Frontiers in Immunology. 9: 1869. doi:10.3389/fimmu.2018.01869. PMC 6099181. PMID 30150991.
Li Y, Li X, Geng X, Zhao H (October 2022). "The IL-2A receptor pathway and its role in lymphocyte differentiation and function". Cytokine & Growth Factor Reviews. 67: 66–79. doi:10.1016/j.cytogfr.2022.06.004. PMID 35803834. S2CID 250252097.
Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD (July 2012). "Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG". European Journal of Immunology. 42 (7): 1893–1905. doi:10.1002/eji.201242444. PMID 22585674.
El-Maraghy N, Ghaly MS, Dessouki O, Nasef SI, Metwally L (August 2018). "CD4+CD25-Foxp3+ T cells as a marker of disease activity and organ damage in systemic lupus erythematosus patients". Archives of Medical Science. 14 (5): 1033–1040. doi:10.5114/aoms.2016.63597. PMC 6111364. PMID 30154885.
Shipkova M, Wieland E (September 2012). "Surface markers of lymphocyte activation and markers of cell proliferation". Clinica Chimica Acta; International Journal of Clinical Chemistry. 413 (17–18): 1338–1349. doi:10.1016/j.cca.2011.11.006. PMID 22120733.
Flynn MJ, Hartley JA (October 2017). "The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer". British Journal of Haematology. 179 (1): 20–35. doi:10.1111/bjh.14770. PMID 28556984.
Jones D, Ibrahim S, Patel K, Luthra R, Duvic M, Medeiros LJ (August 2004). "Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy". Clinical Cancer Research. 10 (16): 5587–5594. doi:10.1158/1078-0432.CCR-0721-03. PMID 15328201.
Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. (March 2013). "Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity". Clinical Immunology. 146 (3): 248–261. doi:10.1016/j.clim.2013.01.004. PMC 3594590. PMID 23416241.
Peerlings D, Mimpen M, Damoiseaux J (2021). "The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis". Journal of Translational Autoimmunity. 4: 100123. doi:10.1016/j.jtauto.2021.100123. PMC 8716671. PMID 35005590.
Kalia V, Sarkar S (2018-12-20). "Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act". Frontiers in Immunology. 9: 2987. doi:10.3389/fimmu.2018.02987. PMC 6306427. PMID 30619342.
Damoiseaux J (September 2020). "The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor". Clinical Immunology. 218: 108515. doi:10.1016/j.clim.2020.108515. PMID 32619646.
Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, et al. (November 2004). "Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma". Blood. 104 (10): 3355–3357. doi:10.1182/blood-2003-11-3922. PMID 15205267.
Kaya H, Kaji M, Usuda D (April 2021). "Soluble interleukin-2 receptor levels on admission associated with mortality in coronavirus disease 2019". International Journal of Infectious Diseases. 105: 522–524. doi:10.1016/j.ijid.2021.03.011. PMC 7942057. PMID 33711520.
Mengel J, Cardillo F, Pontes-de-Carvalho L (2016-05-13). "Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for Which There Is No Treatment". Frontiers in Microbiology. 7: 675. doi:10.3389/fmicb.2016.00675. PMC 4866556. PMID 27242702.
Sahin D, Arenas-Ramirez N, Rath M, Karakus U, Hümbelin M, van Gogh M, et al. (December 2020). "An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer". Nature Communications. 11 (1): 6440. Bibcode:2020NatCo..11.6440S. doi:10.1038/s41467-020-20220-1. PMC 7755894. PMID 33353953.
Pfender N, Martin R (December 2014). "Daclizumab (anti-CD25) in multiple sclerosis" (PDF). Experimental Neurology. 262 (Pt A): 44–51. doi:10.1016/j.expneurol.2014.04.015. PMID 24768797. S2CID 32444028.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Buhelt S, Søndergaard HB, Oturai A, Ullum H, von Essen MR, Sellebjerg F (June 2019). "Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls". Cells. 8 (6): 634. doi:10.3390/cells8060634. PMC 6628508. PMID 31242590.
Qu HQ, Bradfield JP, Bélisle A, Grant SF, Hakonarson H, Polychronakos C (December 2009). "The type I diabetes association of the IL2RA locus". Genes and Immunity. 10 (Suppl 1): S42 – S48. doi:10.1038/gene.2009.90. PMC 2805446. PMID 19956099.
"IL2RA interleukin 2 receptor subunit alpha [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2023-01-25.
Abel AM, Yang C, Thakar MS, Malarkannan S (2018-08-13). "Natural Killer Cells: Development, Maturation, and Clinical Utilization". Frontiers in Immunology. 9: 1869. doi:10.3389/fimmu.2018.01869. PMC 6099181. PMID 30150991.
El-Maraghy N, Ghaly MS, Dessouki O, Nasef SI, Metwally L (August 2018). "CD4+CD25-Foxp3+ T cells as a marker of disease activity and organ damage in systemic lupus erythematosus patients". Archives of Medical Science. 14 (5): 1033–1040. doi:10.5114/aoms.2016.63597. PMC 6111364. PMID 30154885.
Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. (March 2013). "Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity". Clinical Immunology. 146 (3): 248–261. doi:10.1016/j.clim.2013.01.004. PMC 3594590. PMID 23416241.
Peerlings D, Mimpen M, Damoiseaux J (2021). "The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis". Journal of Translational Autoimmunity. 4: 100123. doi:10.1016/j.jtauto.2021.100123. PMC 8716671. PMID 35005590.
"Entrez Gene: IL2RA interleukin 2 receptor, alpha".
Kalia V, Sarkar S (2018-12-20). "Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act". Frontiers in Immunology. 9: 2987. doi:10.3389/fimmu.2018.02987. PMC 6306427. PMID 30619342.
Kaya H, Kaji M, Usuda D (April 2021). "Soluble interleukin-2 receptor levels on admission associated with mortality in coronavirus disease 2019". International Journal of Infectious Diseases. 105: 522–524. doi:10.1016/j.ijid.2021.03.011. PMC 7942057. PMID 33711520.
Mengel J, Cardillo F, Pontes-de-Carvalho L (2016-05-13). "Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for Which There Is No Treatment". Frontiers in Microbiology. 7: 675. doi:10.3389/fmicb.2016.00675. PMC 4866556. PMID 27242702.
Sahin D, Arenas-Ramirez N, Rath M, Karakus U, Hümbelin M, van Gogh M, et al. (December 2020). "An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer". Nature Communications. 11 (1): 6440. Bibcode:2020NatCo..11.6440S. doi:10.1038/s41467-020-20220-1. PMC 7755894. PMID 33353953.

semanticscholar.org

api.semanticscholar.org

Spolski R, Li P, Leonard WJ (October 2018). "Biology and regulation of IL-2: from molecular mechanisms to human therapy". Nature Reviews. Immunology. 18 (10): 648–659. doi:10.1038/s41577-018-0046-y. PMID 30089912. S2CID 51939991.
Zhou P (October 2022). "Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity". Cytokine & Growth Factor Reviews. 67: 80–88. doi:10.1016/j.cytogfr.2022.06.003. PMID 35803833. S2CID 250200065.
Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, et al. (September 2007). "Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes". Nature Genetics. 39 (9): 1074–1082. doi:10.1038/ng2102. PMID 17676041. S2CID 13940200.
Li Y, Li X, Geng X, Zhao H (October 2022). "The IL-2A receptor pathway and its role in lymphocyte differentiation and function". Cytokine & Growth Factor Reviews. 67: 66–79. doi:10.1016/j.cytogfr.2022.06.004. PMID 35803834. S2CID 250252097.
Pfender N, Martin R (December 2014). "Daclizumab (anti-CD25) in multiple sclerosis" (PDF). Experimental Neurology. 262 (Pt A): 44–51. doi:10.1016/j.expneurol.2014.04.015. PMID 24768797. S2CID 32444028.

uniprot.org

"UniProt". www.uniprot.org. Retrieved 2023-01-25.

uzh.ch

zora.uzh.ch

Pfender N, Martin R (December 2014). "Daclizumab (anti-CD25) in multiple sclerosis" (PDF). Experimental Neurology. 262 (Pt A): 44–51. doi:10.1016/j.expneurol.2014.04.015. PMID 24768797. S2CID 32444028.

web.archive.org

"Zinbryta Summary of Product Characteristics" (PDF). European Medicines Agency. 2016. Archived from the original (PDF) on 2018-06-14. Retrieved 2016-12-09.